Stroke Models for Preclinical Trials of Neuroprotective Agents

  • Chung Y. Hsu
  • Yong Y. He
  • Teng N. Lin
  • Grace Wu
  • Paul J. Marangos
Part of the Advances in Neuroprotection book series (AN, volume 22)


With advances in the understanding of the pathophysiology of ischemic brain injury, several therapeutic regimens have been conceived to protect the brain during or following ischemic insult. Despite the numerous claims of therapeutic success in animal models in the past two decades, no therapeutic agents have been approved by the Food and Drug Administration (FDA) for patients with acute ischemic stroke in the United States (Pulsinelli and Buchan, 1989). Lack of success in extrapolating therapeutic efficacy in animal models to stroke patients has raised concern about the validity of using animal stroke models to develop therapeutic regimens (Wiebers et al., 1990). Several recent editorials have extensively discussed the pros and cons of animal stroke models (Graham, 1988; Molinari, 1988; Wiebers et al., 1990; Zivin and Grotta, 1990). An important issue, i.e., the quality of animal trials, however, has not been adequately addressed previously and will be the main focus of this review.


Middle Cerebral Artery Infarct Size Ischemic Insult Neuroprotective Agent Ischemic Brain Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramson NS, Safar P, Detre KM, Kelsey SF, Monroe J, Reinmuth OM, Snyder JV (1986): Brain resuscitation clinical trial I study group: Randomized clinical study of theopental loading in comatose survivors of cardiac arrest. N Engl J Med 314: 397–403.CrossRefGoogle Scholar
  2. Asano T, Gotoh O, Koide T, Takadura K (1985): Ischemic brain edema following occlusion of the middle cerebral artery in the rat. II. Alteration of the eicosanoid synthesis profile of brain microvessels. Stroke 16: 110CrossRefGoogle Scholar
  3. Boxer PA, Cordon JJ, Mann ME, Rodolosi LC, Vartanian MG. Rock DM, Talor CP, Marcoux FW (1990): Comparison of phenytoin with noncompetitive Nmethyl-D-aspartate antagonists in a model of focal brain ischemia in rat. Stroke 21: III 47–51Google Scholar
  4. Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W (1988): Focal brain ischemia in the rat: Methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J Cereb Blood Flow Metab 8: 474–485CrossRefGoogle Scholar
  5. Buchan A, Pulsinelli WA (1990): Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. Neuroscience 10 (1): 311–316CrossRefGoogle Scholar
  6. Busto R, Dietrich WD, Globus MY, Valdes I, Scheinberg P, Ginsberg MD (1987): Small differences in intraischemic brain temperature critically determine the extent of ischemic neuronal injury. J Cereb Blood Flow Metab 7 (6): 729–736CrossRefGoogle Scholar
  7. Chen ST, Hsu CY, Hogan EL, Macriq H, Balentine JD (1986): A model of focal ischemic stroke in the rat: Reproducible extensive cortical infarction. Stroke 17: 738–743CrossRefGoogle Scholar
  8. Ginsberg MD, Castella Y, Dietrich WD, Watson BD, Busto R (1989): Acute thrombotic infarction suppresses metabolic activation of ipsilateral somatosensory cortex: Evidence for functional diaschisis. J Cereb Blood Flow Metab 9: 329–337CrossRefGoogle Scholar
  9. Globus MY, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg, MD (1988): Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and ry-amniobutyric acid studied by intracerebral microdialysis. J Neurochem 51: 1455–1460CrossRefGoogle Scholar
  10. Gotoh O, Asano T, Koide T, Takakura K (1985): Ischemic brain edema following occlusion of the middle cerebral artery in the rat. I. The time courses of the brain water, sodium and potassium contents and blood-brain barrier permeability to 1251-albumin. Stroke 16: 101–110CrossRefGoogle Scholar
  11. Graham DI (1988): Focal cerebral infarction. J Cereb Blood Flow Metab 8: 769–773CrossRefGoogle Scholar
  12. Hsu CY, Faught RE Jr, Furlan BM, Coull BM, Huang DC, Hogan EL, Linet OI, Yatus FM for Prostacyclin Study Group (1987): Intravenous prostacyclin in acute nonhemorrhagic stroke: A placebo-controlled double-blind trial. Stroke 18: 352–358CrossRefGoogle Scholar
  13. Hsu CY, Norris JW, Hogan EL, Bladin P, Dinsdale HB, Yatsu FM, Earnest MP, Scheinberg P, Caplan LR, Karp HR, Swanson PD, Feldman RG, Cohen MM, Mayman CI, Cobert B, Savitsky JP for Pentoxifylline Study Group (1988): Pentoxifylline in acute nonhemorrhagic stroke: A randomized, placebo-controlled double-blind trial. Stroke 19: 716–722CrossRefGoogle Scholar
  14. Jacewicz M, Brint S, Tanabe J, Pulsinelli WA (1990): Continuous nimodipine treatment attenuates cortical infarction in rat subjected to 24 hours of focal cerebral ischemia. J Cereb Blood Flow Metab 10: 89–96CrossRefGoogle Scholar
  15. Jensen ML, Auer RN (1988): The NMDA antagonist ketamine fails to protect against ischaemic neuronal necrosis in the rat. Br J Anaesth 61: 206–212CrossRefGoogle Scholar
  16. Karpiak SE, Tagliavia A, Wakade CG (1989): Animal models for the study of drugs in ischemic stroke. Annu Rev Pharmacol Toxicol 29: 403–414CrossRefGoogle Scholar
  17. Kushner M, Nencini P, Reivich M, Rango M, Jamieson D, Fazekas F, Zimmerman R, Chawluk J, Alavi A, Alves W (1990): Relation of hyperglycemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome. Ann Neurol 28: 129–135CrossRefGoogle Scholar
  18. Levy DE, Brierly JB (1979): Delayed pentobarbital administration limits ischemic brain damage in gerbils. Ann Neurol 5: 59–67CrossRefGoogle Scholar
  19. Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY (1989): Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 256: H589–H593PubMedGoogle Scholar
  20. Marcoux FW, Goodrich JE, Dominick MA (1988): Ketamine prevents ischemic neuronal injury. Brain Res 452: 329–335CrossRefGoogle Scholar
  21. Michenfelder JD, Milde JH (1975): Influence of anesthetics on metabolics, functional and pathological responses to regional cerebral ischemia. Stroke 6: 405–412CrossRefGoogle Scholar
  22. Molinari GF (1986): Experimental models of ischemic stroke. In: Stroke, Pathophysiology, Diagnosis, and Management, Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. New York: Churchill Livingstone, pp 57–73Google Scholar
  23. Molinari GF (1988): Why model strokes? Stroke 19: 1197–1203CrossRefGoogle Scholar
  24. Myers RE, Yamaguchi S (1977): Nervous system effects of cardiac arrest in monkeys. Arch Neurol 34: 65–73CrossRefGoogle Scholar
  25. Nakayama H., Ginsberg MD, Dietrich WD (1988): s-Emopamil, a novel calcium channel blocker and serotonin SZ antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat. Neurology 38: 1667–1673CrossRefGoogle Scholar
  26. Pulsinelli WA, Brierly JB (1979): A new model of bilateral hemisphereal ischemia in the unanesthetized rat. Stroke 10: 267–272CrossRefGoogle Scholar
  27. Pulsinelli WA, Buchan A (1989): The utility of animal ischemia models in predicting pharmacotherapeutic response in the clinical setting. In: Cerebrovascular Diseases, Ginsberg MD, Dietrich WD, eds. New York: Raven Press, pp 87–91Google Scholar
  28. Reimer KA, Jennings RB, Cobb FR, Murdock RH, Greenfield Jr JC, Becker LC, Bulkley BH, Hutchins GM, Schwartz Jr RP, Bailey KR, Passamani ER (1985): Animal models for protecting ischemic myocardium: Results of the NHLBI Cooperative Study. Circ Res 56: 651–665CrossRefGoogle Scholar
  29. Schallert T, Jones TA, Linder MD (1990): Multilevel transneuronal degeneration after brain damage: Behavioral events and effects of anticonvulsant -y-aminobutyric acid-related drugs. Stroke 21: III 143–146Google Scholar
  30. Volpe BT, Davis HP (1989): An approach to the functional analysis of an animal model of ischemic injury. In: Cerebrovascular Diseases, Ginsberg MD, Dietrich WD, eds. New York: Raven Press, pp 335–340Google Scholar
  31. Waltz AG (1979): Clinical relevance of models of cerebral ischemia. Stroke 10: 211–218CrossRefGoogle Scholar
  32. Weiss J, Goldberg MP, Choi DW (1986): Ketamine protects cultured neocortical neurons from hypoxic injury. Brain Res 380: 186–192CrossRefGoogle Scholar
  33. Wiebers BO, Adams HP Jr, Whisnant JP (1990): Animal models of stroke: Are they relevant to human disease? Stroke 21: 1–5CrossRefGoogle Scholar
  34. Yip PK, He YY, Hsu CY, Garg N, Marangos P, Hogan EL (1991): Effect of plasma glucose on infarct size in focal cerebral ischemia-reperfusion. Neurology 41: 899–905CrossRefGoogle Scholar
  35. Zivin JA, Grotta JC (1990): Animal stroke models: They are relevant to human disease. Stroke 21: 981–983CrossRefGoogle Scholar
  36. Zivin JA, Fisher M, DeGivolami U, Hemeway CG, Stashak JA (1985): Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230: 1289–1292ADSCrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1992

Authors and Affiliations

  • Chung Y. Hsu
  • Yong Y. He
  • Teng N. Lin
  • Grace Wu
  • Paul J. Marangos

There are no affiliations available

Personalised recommendations